Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 20:8:680871.
doi: 10.3389/fmed.2021.680871. eCollection 2021.

Risk Factors for Mucosal Involvement in Bullous Pemphigoid and the Possible Mechanism: A Review

Affiliations
Review

Risk Factors for Mucosal Involvement in Bullous Pemphigoid and the Possible Mechanism: A Review

Xinyi Chen et al. Front Med (Lausanne). .

Abstract

Bullous pemphigoid (BP) is the most common type of autoimmune bullous disease and is characterized by the presence of circulating anti-BP180 and/or anti-BP230 autoantibodies. Patients with BP often present with tense blisters and erythema, mainly on the trunk and limbs, but a few patients also have mucosal involvement. In this article, we discuss the fact that BP patients with mucosal involvement tend to have more serious conditions and their disease is more difficult to control. Potential risk factors for mucous involvement include earlier age at onset, drugs such as dipeptidyl peptidase-4 inhibitors, cancer, and blood/serum biomarkers, including lower eosinophil count, higher erythrocyte sedimentation rate, IgG autoantibodies against both the NH2- and COOH-termini of BP180, and the absence of anti-BP230 antibodies. IgA and C3 deposition at the dermo-epidermal junction may also be present. Understanding these risk factors may benefit earlier diagnosis of these patients and promote the development of novel treatments. What's more, it's helpful in deeper understanding of BP development and the relationship between BP and mucous membrane pemphigoid (MMP).

Keywords: autoantibody; bullous pemphigoid; mucous; risk factors; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Factors that may influence mucosal involvement. EOS, eosinophil; PLT, platelet; WBC, white blood cell; ESR, erythrocyte sedimentation rate.

References

    1. Kridin K, Ludwig RJ. The growing incidence of bullous pemphigoid: overview and potential explanations. Front Med (Lausanne). (2018) 5:220. 10.3389/fmed.2018.00220 - DOI - PMC - PubMed
    1. Baigrie D, Nookala V. Bullous Pemphigoid. StatPearls. Treasure Island, FL: StatPearls Publishing Copyright © 2020, StatPearls Publishing LLC; (2020). - PubMed
    1. Miyamoto D, Santi CG, Aoki V, Maruta CW. Bullous pemphigoid. An Bras Dermatol. (2019) 94:133–46. 10.1590/abd1806-4841.20199007 - DOI - PMC - PubMed
    1. Lopez AT, Khanna T, Antonov N, Audrey-Bayan C, Geskin L. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol. (2018) 57:664–9. 10.1111/ijd.13984 - DOI - PubMed
    1. Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Front Immunol. (2019) 10:1238. 10.3389/fimmu.2019.01238 - DOI - PMC - PubMed